Literature DB >> 3082933

Plasma cholesterol metabolism in end-stage renal disease. Difference between treatment by hemodialysis or peritoneal dialysis.

H Dieplinger, P Y Schoenfeld, C J Fielding.   

Abstract

Plasma cholesterol metabolism was investigated in normotriglyceridemic patients with end-stage renal disease treated by hemo- or continuous ambulatory peritoneal dialysis (CAPD), and compared with that in a control group with normal renal function. A reversed net transport of free cholesterol from plasma to cultured fibroblasts, as well as greatly reduced levels of plasma cholesterol esterification and cholesterol ester transfer rates to low and very low density lipoproteins (LDL and VLDL), was found in the hemodialysis group compared to the controls. The LDL and VLDL contained increased amounts of free cholesterol and inhibited cholesterol ester transfer when recombined with control plasma. The LDL triglyceride content was doubled in the hemodialysis group, whereas cholesterol esters were decreased. Patients treated by CAPD, in marked contrast, had cholesterol metabolic rates that were within the normal range, as well as normal lipoprotein composition.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3082933      PMCID: PMC424441          DOI: 10.1172/JCI112406

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  31 in total

1.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

2.  The picomole determination of free and total cholesterol in cells in culture.

Authors:  J G Heider; R L Boyett
Journal:  J Lipid Res       Date:  1978-05       Impact factor: 5.922

3.  Defective high-density lipoprotein composition in patients on chronic hemodialysis. A possible mechanism for accelerated atherosclerosis.

Authors:  J Rapoport; M Aviram; C Chaimovitz; J G Brook
Journal:  N Engl J Med       Date:  1978-12-14       Impact factor: 91.245

4.  Editoral: Cardiovascular disease in dialysis patients.

Authors:  E G Lowrie; J M Lazarus; C L Hampers; J P Merrill
Journal:  N Engl J Med       Date:  1974-03-28       Impact factor: 91.245

5.  Hypertriglyceridemia. A metabolic consequence of chronic renal failure.

Authors:  J D Bagdade; D Porte; E L Bierman
Journal:  N Engl J Med       Date:  1968-07-25       Impact factor: 91.245

6.  Human plasma lecithin-cholesterol acyltransferase. Characterization of cofactor-dependent phospholipase activity.

Authors:  L Aron; S Jones; C J Fielding
Journal:  J Biol Chem       Date:  1978-10-25       Impact factor: 5.157

7.  Characterization of human very low density lipoproteins containing two electrophoretic populations: double pre-beta lipoproteinemia and primary dysbetalipoproteinemia.

Authors:  A Pagnan; R J Havel; J P Kane; L Kotite
Journal:  J Lipid Res       Date:  1977-09       Impact factor: 5.922

8.  The measurement of apolipoprotein A-I and A-II levels in men and women by immunoassay.

Authors:  M C Cheung; J J Albers
Journal:  J Clin Invest       Date:  1977-07       Impact factor: 14.808

9.  Prevalence of serum lipid abnormalities in chronic hemodialysis.

Authors:  J D Brunzell; J J Albers; L B Haas; A P Goldberg; L Agadoa; D J Sherrard
Journal:  Metabolism       Date:  1977-08       Impact factor: 8.694

10.  The interaction of heparin with an apoprotein of human very low density lipoprotein.

Authors:  F A Shelburne; S H Quarfordt
Journal:  J Clin Invest       Date:  1977-10       Impact factor: 14.808

View more
  11 in total

Review 1.  Interaction of lipid transfer protein with plasma lipoproteins and cell membranes.

Authors:  R E Morton
Journal:  Experientia       Date:  1990-06-15

2.  Dialysis Modalities and HDL Composition and Function.

Authors:  Michael Holzer; Gernot Schilcher; Sanja Curcic; Markus Trieb; Senka Ljubojevic; Tatjana Stojakovic; Hubert Scharnagl; Chantal M Kopecky; Alexander R Rosenkranz; Akos Heinemann; Gunther Marsche
Journal:  J Am Soc Nephrol       Date:  2015-03-05       Impact factor: 10.121

Review 3.  Emerging risk factors and markers of chronic kidney disease progression.

Authors:  Florian Kronenberg
Journal:  Nat Rev Nephrol       Date:  2009-12       Impact factor: 28.314

4.  Isolation and specificity of a Mr 74,000 cholesteryl ester transfer protein from human plasma.

Authors:  A S Jarnagin; W Kohr; C Fielding
Journal:  Proc Natl Acad Sci U S A       Date:  1987-04       Impact factor: 11.205

5.  Lipoprotein kinetics in male hemodialysis patients treated with atorvastatin.

Authors:  Johannes P Schwaiger; Yoshinobu Nakada; Ramona Berberich; Katsunori Ikewaki; Benjamin Dieplinger; Emanuel Zitt; Ulrich Neyer; Hermann Salmhofer; Florian Kronenberg; Paul Koenig; Hans Dieplinger
Journal:  Clin J Am Soc Nephrol       Date:  2013-04-18       Impact factor: 8.237

6.  Elevated plasma concentrations of lipoprotein(a) in patients with end-stage renal disease are not related to the size polymorphism of apolipoprotein(a).

Authors:  H Dieplinger; C Lackner; F Kronenberg; C Sandholzer; K Lhotta; F Hoppichler; H Graf; P König
Journal:  J Clin Invest       Date:  1993-02       Impact factor: 14.808

Review 7.  Lipoprotein (a): impact by ethnicity and environmental and medical conditions.

Authors:  Byambaa Enkhmaa; Erdembileg Anuurad; Lars Berglund
Journal:  J Lipid Res       Date:  2015-12-04       Impact factor: 5.922

Review 8.  Disturbances of lipid metabolism in children with chronic renal failure.

Authors:  U Querfeld
Journal:  Pediatr Nephrol       Date:  1993-12       Impact factor: 3.714

9.  Effects of hemodialysis on serum lipids and phospholipids of end-stage renal failure patients.

Authors:  C Piperi; C Kalofoutis; M Tzivras; T Troupis; A Skenderis; A Kalofoutis
Journal:  Mol Cell Biochem       Date:  2004-10       Impact factor: 3.396

10.  Coronary risk factors in maintenance hemodialysis patients: Who is the culprit - hemodialysis or chronic renal failure?

Authors:  Kapil Gupta; Rajiv Mahajan
Journal:  Int J Appl Basic Med Res       Date:  2011-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.